Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

Andrea Casadei Gardini, Emanuela Scarpi, Luca Faloppi, Mario Scartozzi, Nicola Silvestris, Daniele Santini, G. De Stefano, Giorgia Marisi, Francesca V. Negri, Francesco Giuseppe Foschi, Martina Valgiusti, G. Ercolani, Giovanni Luca Paolo Frassineti

Research output: Contribution to journalArticle

Abstract

We evalueted a systemic immune-inflammation index (SII), neutrophil-tolymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360. NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.

Original languageEnglish
Pages (from-to)67142-67149
Number of pages8
JournalOncotarget
Volume7
Issue number41
DOIs
Publication statusPublished - 2016

Fingerprint

Hepatocellular Carcinoma
Neutrophils
Inflammation
Blood Platelets
Lymphocytes
sorafenib
Therapeutics

Keywords

  • Biomarker
  • Hepatocellular carcinoma
  • Inflammation
  • Neutrophil-to-lymphocyte ratio
  • Systemic immune-inflammation index

ASJC Scopus subject areas

  • Oncology

Cite this

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. / Gardini, Andrea Casadei; Scarpi, Emanuela; Faloppi, Luca; Scartozzi, Mario; Silvestris, Nicola; Santini, Daniele; De Stefano, G.; Marisi, Giorgia; Negri, Francesca V.; Foschi, Francesco Giuseppe; Valgiusti, Martina; Ercolani, G.; Frassineti, Giovanni Luca Paolo.

In: Oncotarget, Vol. 7, No. 41, 2016, p. 67142-67149.

Research output: Contribution to journalArticle

Gardini, Andrea Casadei ; Scarpi, Emanuela ; Faloppi, Luca ; Scartozzi, Mario ; Silvestris, Nicola ; Santini, Daniele ; De Stefano, G. ; Marisi, Giorgia ; Negri, Francesca V. ; Foschi, Francesco Giuseppe ; Valgiusti, Martina ; Ercolani, G. ; Frassineti, Giovanni Luca Paolo. / Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. In: Oncotarget. 2016 ; Vol. 7, No. 41. pp. 67142-67149.
@article{7c89bb012f5247e2b58c44afcc8d2709,
title = "Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib",
abstract = "We evalueted a systemic immune-inflammation index (SII), neutrophil-tolymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360. NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.",
keywords = "Biomarker, Hepatocellular carcinoma, Inflammation, Neutrophil-to-lymphocyte ratio, Systemic immune-inflammation index",
author = "Gardini, {Andrea Casadei} and Emanuela Scarpi and Luca Faloppi and Mario Scartozzi and Nicola Silvestris and Daniele Santini and {De Stefano}, G. and Giorgia Marisi and Negri, {Francesca V.} and Foschi, {Francesco Giuseppe} and Martina Valgiusti and G. Ercolani and Frassineti, {Giovanni Luca Paolo}",
year = "2016",
doi = "10.18632/oncotarget.11565",
language = "English",
volume = "7",
pages = "67142--67149",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "41",

}

TY - JOUR

T1 - Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

AU - Gardini, Andrea Casadei

AU - Scarpi, Emanuela

AU - Faloppi, Luca

AU - Scartozzi, Mario

AU - Silvestris, Nicola

AU - Santini, Daniele

AU - De Stefano, G.

AU - Marisi, Giorgia

AU - Negri, Francesca V.

AU - Foschi, Francesco Giuseppe

AU - Valgiusti, Martina

AU - Ercolani, G.

AU - Frassineti, Giovanni Luca Paolo

PY - 2016

Y1 - 2016

N2 - We evalueted a systemic immune-inflammation index (SII), neutrophil-tolymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360. NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.

AB - We evalueted a systemic immune-inflammation index (SII), neutrophil-tolymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360. NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.

KW - Biomarker

KW - Hepatocellular carcinoma

KW - Inflammation

KW - Neutrophil-to-lymphocyte ratio

KW - Systemic immune-inflammation index

UR - http://www.scopus.com/inward/record.url?scp=84993997499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993997499&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11565

DO - 10.18632/oncotarget.11565

M3 - Article

VL - 7

SP - 67142

EP - 67149

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 41

ER -